Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Increasing Preference for Minimally Invasive Procedures
5.2.2 Rising Prevalence of Chronic Disorders
5.2.3 Improvement in Reimbursement Scenario
5.2.4 Rising Geriatric Population
5.3 Restraints
5.3.1 Rising Treatment Cost and Hospital Stay
5.3.2 Lack of Skilled Physicians
5.4 Opportunities
5.4.1 New Advancements in Catheterization Devices
5.4.2 Guide Wire Assisted Surgery in Elderly Population
5.1 Mega Trends
5.1.1 Telemedicine
5.2 Macroeconomic Indicators
5.3 Technology Trends & Assessment
?
6 Market Factor Analysis
6.1 Porter's Five Forces Model
6.1.1 Threat of New Entrants
6.1.2 Bargaining Power of Suppliers
6.1.3 Threat of Substitutes
6.1.4 Bargaining Power of Buyers
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 Research &Development
6.2.2 Manufacturing
6.2.3 Distribution
6.2.4 Marketing & Sales
6.2.5 Post-Sales Monitoring
6.3 Demand & Supply: Gap Analysis
6.4 Pricing Analysis
6.5 Investment Feasibility Analysis
7 Global Transient Ischemic Attack Market, by Diagnosis
7.1 Introduction
7.2 Imaging Techniques
7.2.1 Computed Tomography (CT) scan
7.2.2 Carotid Duplex Scanning
7.2.3 Magnetic Resonance Imaging
7.2.4 Echocardiography
8 Global Transient Ischemic Attack Market, by Treatment
8.1 Introduction
8.2 Surgery
8.3 Drugs
8.3.1 Surgery
8.3.2 Drugs
8.3.2.1 Antithrombotic agents
8.3.2.2 Antiplatelets
8.3.2.3 Clopidogrel
8.3.2.4 Aspirin
8.3.2.5 Heparins
8.3.2.6 ENOXAPARIN
8.3.2.7 DALTEPARIN
8.3.2.8 Fibrinolytics
8.3.2.9 Tenecteplase
8.3.2.10 Alteplase
8.3.2.11 Antihypertensive agents
8.3.2.12 Prazosin
8.3.2.13 Moxonidine
9 Global Transient Ischemic Attack Market, by Age Groups
9.1 Introduction
9.2 0-18 years
9.3 19-40 years (Millennial)
9.4 41-60 years
9.5 60+ years
9.5.1 0-18 years
9.5.2 19-40 years
9.5.3 41-60 years
9.5.4 60+ years
10 Global Transient Ischemic Attack Market, by End-User
10.1 Introduction
10.2 Hospitals & Clinics
10.3 Diagnostic Centers
10.4 Research Laboratories
10.4.1 Hospitals
10.4.2 Diagnostic Centers
10.4.3 Research Laboratories
11 Global Transient Ischemic Attack Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
?
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 United Arab Emirates
11.5.3 Saudi Arabia
11.5.4 Rest of Middle East & Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Company Share Analysis
12.3 Recent Developments, 2013-2018
13 Company Profiles
13.1 Koninklijke Philips N.V.
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Stryker Corporation
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Johnson & Johnson Services Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
13.4 Boston Scientific Corporation
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Sanofi
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Bayer AG
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Pfizer Inc.
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Siemens AG
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 F. Hoffmann-La Roche AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 GE Healthcare
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Penumbra, Inc.
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
13.12 Medtronic PLC
13.12.1 Company Overview
13.12.2 Financial Overview
13.12.3 Products Offering
13.12.4 Key Developments
13.12.5 SWOT Analysis
13.12.6 Key Strategy
13.13 Abbott Laboratories
13.13.1 Company Overview
13.13.2 Financial Overview
13.13.3 Products Offering
13.13.4 Key Developments
13.13.5 SWOT Analysis
13.13.6 Key Strategy
13.14 Merck & Co., Inc.
13.14.1 Company Overview
13.14.2 Financial Overview
13.14.3 Products Offering
13.14.4 Key Developments
13.14.5 SWOT Analysis
13.14.6 Key Strategy
13.15 Boehringer Ingelheim GmbH
13.15.1 Company Overview
13.15.2 Financial Overview
13.15.3 Products Offering
13.15.4 Key Developments
13.15.5 SWOT Analysis
13.15.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO's Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.2 References